Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Conditions:   Cervical Cancers;   Vulvar Cancer;   Vaginal Cancer;   CIN1;   CIN2;   CIN 3;   AIS;   Invasive Carcinoma;   Mild Dysplasia of Vulva;   Moderate Dysplasia of Vulva;   Vin III;   VaIN1;   VaIN2;   VaIN3;   Genital Wart Interventions:   Biological: 9-valent HPV Recombinant Vaccine;   Biological: Placebo Sponsors:   Shanghai Bovax Biotechnology Co., Ltd.;   Chongqing Bovax Biopharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials